

primary studies - published RCT

## Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic *P. aeruginosa* infection.

**Code:** PM34144923

**Year:** 2021 **Date:**

**Author:** Bilton D

### Study design (if review, criteria of inclusion for studies)

Extension of a phase 3, randomised, open-label study

### Participants

Patients with cystic fibrosis (CF) and chronic *Pseudomonas aeruginosa* infection

### Interventions

In CLEAR-108-a phase 3, randomised, open-label study-once-daily amikacin liposome inhalation suspension (ALIS) was noninferior to twice-daily tobramycin inhalation solution (TIS) in improving lung function in patients with cystic fibrosis (CF) and chronic *Pseudomonas aeruginosa* infection after 3 treatment cycles (28 days on/28 days off). The CLEAR-110 extension study assessed long-term safety, tolerability, and efficacy of ALIS in eligible patients who completed CLEAR-108. Patients received once-daily ALIS 590 mg for 12 treatment cycles (96 weeks). Patients were grouped by prior treatment: the "prior-ALIS" cohort received ALIS in CLEAR-108, and the "ALIS-naïve" cohort received TIS in CLEAR-108.

### Outcome measures

Long-term safety, tolerability, and efficacy of ALIS

### Main results

206 patients (prior-ALIS, n=92; ALIS-naïve, n=114) entered CLEAR-110 and received at least one dose of ALIS. Most patients (88.8%) experienced at least one treatment-emergent adverse event (TEAE) through day 672 (end of year 2). Most TEAEs (72.3%) were mild or moderate in severity. Severe TEAEs were reported in 31 patients (15.0%). Two life-threatening TEAEs (haemoptysis; intestinal obstruction) and 1 death (cardiac failure) were reported. Twenty-one patients (10.2%) discontinued treatment due to a TEAE (mostly infective pulmonary exacerbation of CF). Mean change from baseline in forced expiratory volume in 1 second percent predicted at day 672 was -3.1% (prior-ALIS, -4.0%; ALIS-naïve, -2.3%). Mean change from baseline in sputum density of *P. aeruginosa* at day 672 was 0.02 (prior-ALIS, -0.16; ALIS-naïve, 0.19) log CFU/g.

### Authors' conclusions

Long-term treatment with ALIS was well tolerated with a favourable adverse event profile and demonstrated continued antibacterial activity in CF patients with chronic *P. aeruginosa* infection.

<http://dx.doi.org/10.1016/j.jcf.2021.05.013>

### See also

J Cyst Fibros. 2021 Nov;20(6):1010-1017. doi: 10.1016/j.jcf.2021.05.013. Epub 2021 Jun 16.

### Keywords

Amikacin; Anti-Bacterial Agents; ariace; Liposomal amikacin; Bacterial Infections; Infection; Inhalation OR nebulised; pharmacological\_intervention; placebo; *Pseudomonas aeruginosa*; *Pseudomonas*; Respiratory Tract Diseases; Respiratory Tract Infections; Aminoglycosides; Liposomal Amikacin;